Arcus Biosciences (NYSE:RCUS) presented its corporate update on February 25, 2025, showcasing its oncology pipeline and development strategy. The presentation comes at a challenging time for the ...

The investigation into the alleged cover-up of former President Joe Biden's mental decline is deepening with nine former White House officials to testify.

On June 1, Arcus Biosciences presented the first data for casdatifan plus cabozantinib in oral metastatic kidney cancer, which showed a confirmed response.

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry ...